



Understanding bladder pain syndrome/interstitial cystitis

Visha Tailor¹ · Marco Torella² · Valentin Manriquez³ · Giuseppe Alessandro Digesu¹

Published online: 24 February 2020

© The International Urogynecological Association 2020

Abbreviations

BPS Bladder pain syndrome

IC Interstitial cystitis

In 1887, Dr. Alexander Skene introduced the concept and disease “interstitial cystitis,” describing inflammation that destroys the mucous membrane partly or wholly and extends to the muscular parietes. Over time, the core definition has evolved to include ulcerations [1], chronic symptoms including pain [2], glomerulations [3], and finally the umbrella concept of painful bladder syndrome (ICS 2002) or bladder pain syndrome (The European Society for the Study of Interstitial Cystitis 2006) as it is now termed [4].

Bladder pain is defined as the complaint of suprapubic or retropubic pain, pressure, or discomfort, related to the bladder, and usually increasing with bladder filling. It may persist or be relieved after voiding. When symptoms are associated with urinary symptoms such as urgency, frequency, and nocturia, the diagnosis of bladder pain syndrome (BPS) is given [5]. International societies vary in their opinion of the duration of symptoms, from 6 weeks (American Urological Association [6]) to 6 months (European Society for the Study of Bladder Pain Syndrome), but all agree the diagnosis is given in the absence of identifiable pathology or causes. The symptoms of BPS have a significant impact on a patient’s quality of life and can also be associated with additional pain syndromes, such as vulvodynia and fibromyalgia [7, 8].

Interstitial cystitis (IC) remains a considered diagnosis and a possible phenotype or subtype under the overall diagnosis of

BPS. Features of IC include bladder ulcerations, with the original description given by Hunner in 1915 as the appearance of patches of red mucosa exhibiting small vessels radiating to a central pale scar [1].

Cystoscopy is recommended in the investigation of BPS/IC to exclude alternative causes of the presentation, such as bladder carcinoma, endometriosis, infection, and bladder stones [4, 5], but not for diagnosis [4]. Low anaesthetic bladder capacity is associated with BPS/IC and may even form a separate subtype in patients with disease symptoms [9]. Bladder biopsy may reveal associated histological changes, such as a degree of denuded epithelium, ulceration, chronic inflammation, and raised mast cell count [4, 9]. However, one can have pathology consistent with the diagnosis of BPS, but there is no histology that is pathognomonic of this syndrome.

As is the case with a broad definition and wide range of clinical findings, there are challenges in clinical and basic science research as well as for the clinician managing patients with BPS/IC. In recent studies on the aetiology of BSP/IC, potential biomarkers have been identified from urine, stool and bladder biopsy specimens; however further research into these biomarkers and their association with clinical severity and impact are required [10, 11]. The study of the urinary microbiome in urogynaecology has become a recent focus [12–15], but no significant urobiome differences among patients with BPS/IC have so far been identified [15].

The likely multi-factorial aetiology results in a wide range of available management options.

General relaxation, stress and pain management, patient education, self-care and behavioural modification, a low-histamine diet, as well as manual physical therapy/trigger point techniques are often first-line, non-invasive treatment methods. Medical management includes anti-histamines (i.e. cimetidine, hydroxyzine), antidepressants (i.e. amitriptyline, duloxetine), pentosan polysulfate, as well as pain management treatments (i.e. gabapentin and pregabalin).

Intravesical treatments with instillations using hyaluronic acid, chondroitin sulfate, dimethyl sulfoxide, corticosteroid (e.g. hydrocortisone, triamcinolone), lidocaine and heparin have been found to be effective in treating symptoms [16];

✉ Visha Tailor
visha_tailor@yahoo.co.uk

¹ Imperial College Healthcare, Department of Urogynaecology, St Mary’s Hospital, London, UK

² Department of Obstetrics and Gynecology, Luigi Vanvitelli University of Campania, Naples, Italy

³ Pelvic Floor Unit, Obstetrics and Gynecology Department, Clinical Hospital, Universidad de Chile, Santiago, Chile

however, the best combination, dosage, and frequency are yet to be determined.

Bladder dome or trigone injection with Botulinum toxin A, a neurotoxin, and triamcinolone, particularly in the presence of ulceration, have been studied [17, 18]. Both have shown treatment benefit with a reduction in bladder pain; however, both are not curative and require repeated treatment. Risks of urinary tract infection, dysuria and urine retention have been reported with the use of Botulinum toxin [17].

If ulcerations are identified at cystoscopy, transurethral fulguration or ablation or resection is recommended, producing symptom improvement in 50–81% of treated patients [18]. Medically recalcitrant cases may be suitable for sacral neuromodulation. Success rates, particularly with optimized protocols to include motor response with low (≤ 3 V) voltage stimulation, can produce clinical benefit, with a reduction in visual analogue pain scores and validated symptom questionnaire scores in up to 95% of patients [19].

Resistant cases may benefit from adjuvant treatment with cyclosporine, which inhibits production and release of lymphokines and therefore suppresses cell-mediated immune response. The last line of treatment is surgery, which can include urinary diversion without cystectomy, augmentation ileocystoplasty and cystectomy [20].

There is still much to understand on the topic of BPS/IC. In response to Hunner, the scientific community has “awakened to its existence” and made encouraging steps towards identifying the aetiology and optimizing treatment of this “...condition which is not so rare” [21].

References

- Hunner GL. A Rare Type of Bladder Ulcer in Women; Report of Cases. *The Boston Medical and Surgical Journal* 1915; 172 (18): 660–664
- Bourque JP. Surgical Management of the Painful Bladder. *Journal of Urology* 1951; 65 (1):25–35
- Messing EM, Stamey TA. Interstitial cystitis early diagnosis, pathology, and treatment. *Urology* 1978; 12 (4):381–392
- Abrams P, Cardozo L, Wagg A, Wein A, editors. *Incontinence*, 6th ed. International Continence Society, Bristol. 2017.
- Pape J, Falconi G, et al. Variations in bladder pain syndrome/interstitial cystitis (IC) definitions, pathogenesis, diagnostics and treatment: a systematic review and evaluation of national and international guidelines. *Int Urogynecol J*. 2019;30(11):1795–805. <https://doi.org/10.1007/s00192-019-03970-5>.
- Sun Y, Harlow BL. The association of vulvar pain and urological urgency and frequency: findings from a community-based case-control study. *Int Urogynecol J*. 2019;30(11):1871–8. <https://doi.org/10.1007/s00192-019-04052-2>.
- Hanno PM, Erickson D, Moldwin R, Faraday MM, American Urological Association. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. *J Urol*. 2015;193(5):1545–53. <https://doi.org/10.1016/j.juro.2015.01.086>.
- Matthews C, Deveshwar SP, Evans RJ, Badlani G, Walker SJ. Small fibre polyneuropathy as a potential therapeutic target in interstitial cystitis/bladder pain syndrome. *Int Urogynecol J*. 2019;30(11):1817–20. <https://doi.org/10.1007/s00192-019-04011-x>.
- Schachar JS, Evans RJ, Parks GE, Zambon J, Badlani G, Walker SJ. Histological evidence supports low anesthetic bladder capacity as a marker of a bladder-centric disease subtype in interstitial cystitis/bladder pain syndrome. *Int Urogynecol J*. 2019;30(11):1863–70. <https://doi.org/10.1007/s00192-019-04038-0>.
- Liu S, Feng S, Luo D. Analysis of key genes and micro-RNA-mRNA regulatory networks in women with ulcerative interstitial cystitis/pain bladder syndrome. *Int Urogynecol J*. 2019;30(9):1487–95. <https://doi.org/10.1007/s00192-018-3817-x>.
- Magalhaes TF, Baracat EC, Doumouchtsis SK, Haddad JM. Biomarkers in the diagnosis and symptom assessment of patients with bladder pain syndrome: a systematic review. *Int Urogynecol J*. 2019;30(11):1785–94. <https://doi.org/10.1007/s00192-019-04075-9>.
- Fok CS, Gao X, Lin H, Thomas-White KJ, Mueller ER, Wolfe AJ, et al. Urinary symptoms are associated with certain urinary microbes in urogynecologic surgical patients. *Int Urogynecol J*. 2018;29(12):1765–71. <https://doi.org/10.1007/s00192-018-3732-1>.
- Chen Z, Phan MD, Bates LJ, Peters KM, Mukerjee C, Moore KH, et al. The urinary microbiome in patients with refractory urge incontinence and recurrent urinary tract infection. *Int Urogynecol J*. 2018;29(12):1775–82. <https://doi.org/10.1007/s00192-018-3679-2>.
- Komesu YM. The urinary microbiome in women with mixed urinary incontinence compared to similarly aged controls. *Int Urogynecol J*. 2018;29(12):1785–95. <https://doi.org/10.1007/s00192-018-3683-6>.
- Bresler L, Price TK, Hilt EE, Joyce C, Fitzgerald CM, Wolfe AJ. Female lower urinary tract microbiota do not associate with IC/PBS symptoms: a case-controlled study. *Int Urogynecol J*. 2019;30(11):1835–42. <https://doi.org/10.1007/s00192-019-03942-9>.
- Arslan B, Gönültaş S, Gökmen E, Özman O, Avci MA, Özdemir E. Outcomes of intravesical chondroitin-sulfate and combined hyaluronic-acid/chondroitin-sulfate therapy on female sexual function in bladder pain syndrome. *Int Urogynecol J*. 2019;30(11):1857–62. <https://doi.org/10.1007/s00192-019-04036-2>.
- Shim SR, Cho YJ, Shin IS, Kim JH. Efficacy and safety of botulinum toxin injection for interstitial cystitis/bladder pain syndrome: a systematic review and meta-analysis. *Int Urol Nephrol*. 2016;48(8):1215–27. <https://doi.org/10.1007/s11255-016-1295-y>.
- Crescenze IM, Gupta P, Adams G, Oldendorf A, Stoffel JT, Romo PGB, et al. Advanced management of patients with ulcerative interstitial cystitis/bladder pain syndrome. *Urology*. 2019;<https://doi.org/10.1016/j.urology.2019.07.036>.
- Marinkovic SP. Improving clinical outcomes with lower motor voltage (≤ 3 V) during stage 1 sacral neuromodulation for interstitial cystitis or bladder pain syndrome. *Neurourol Urodyn*. 2019;38(8):2233–41. <https://doi.org/10.1002/nau.24123>.
- Redmond EJ, Flood HD. The role of reconstructive surgery in patients with end-stage interstitial cystitis/bladder pain syndrome: is cystectomy necessary? *Int Urogynecol J*. 2017;28(10):1551–6. <https://doi.org/10.1007/s00192-017-3307-6>.
- Hunner GL. A rare type of bladder ulcer further notes, with a report of eighteen cases. *JAMA*. 1918;70(4):203–12. <https://doi.org/10.1001/jama.1918.02600040001001>.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.